Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2025-12-27 @ 11:18 PM
Study NCT ID:
NCT07298993
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-12-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Sponsor:
Weill Medical College of Cornell University
Organization:
Study Overview
Official Title:
Determining Evidence in a Placebo-Controlled, Randomized Experiment Studying Continuation vs. Removal of Inessential Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DEPRESCRIBE
Brief Summary:
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.
Participants will be randomly assigned to one of two groups:
Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.
Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.
All participants will:
* Take study medicine for about 4 months
* Have their blood pressure and heart rate monitored
* Complete regular phone calls and questionnaires about how they are feeling
This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
Participants will be randomly assigned to one of two groups:
Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.
Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.
All participants will:
* Take study medicine for about 4 months
* Have their blood pressure and heart rate monitored
* Complete regular phone calls and questionnaires about how they are feeling
This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01AG091005 | NIH | None | https://reporter.nih.gov/quic… | View |